BioMarin Pharmaceutical NASDAQ: BMRN is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about competition for its VOXZOGO treatment.
BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference.
BioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion.
Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,538 shares of the biotechnology company's stock, valued at approximately $1,052,000. Other hedge funds and other institutional investors also recently added to
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an increase of approximately 228% compared to the typical daily volume of 1,206 call options. BioMarin Pharmaceutical News Summary Here are the key news stories impacting
BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.
Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.